Cancer News: Head and neck
Researchers at the National Institutes of Health (NIH), Bethesda, MD, have taken the first steps to determine if a protein, called Programmed Death Ligand 1 (PD-L1), can help to predict which thyroid cancer patients will most likely have a recurrence of the disease. Study findings were presented at the 2013 Clinical Congress of the American College of Surgeons.
Examining 12 major types of cancer, scientists at Washington University School of Medicine in St. Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of a range of tumors in the body. The discovery sets the stage for devising new diagnostic tools and more personalized cancer treatments.
The U.S. Food and Drug Administration today expanded the approved uses of sorafenib (Nexavar) to treat late-stage differentiated thyroid cancer. The new indication is for patients with locally recurrent or metastatic, progressive differentiated thyroid cancer that no longer responds to radioactive iodine treatment.
In Europe in 2012, there were an estimated 39,900 new cases of laryngeal cancer and 99,600 new cases of oral cavity and pharyngeal cancers. These types of cancers can negatively affect the health related quality of life (HRQOL), because they induce symptoms that may interfere with daily life.
The FDA approved an expanded indication for the targeted cancer drug sorafenib (Nexavar) to treat metastatic, differentiated thyroid cancer.
A small study has shown that patients with tongue cancer benefit more from surgery followed by radiation therapy, compared to starting treatment with chemotherapy.
Patients with tongue cancer who started treatment with surgery had better outcomes compared to those who had chemotherapy first, according to researchers.
Thyroid cancer diagnosed in minorities and people of low socioeconomic status is more likely to be at advanced stage.
Head and neck cancer patients receiving intensity-modulated radiation therapy (IMRT) experience fewer side effects and have better overall survival compared to standard radiotherapy.
Radiation therapy on one side of the neck for advanced stage tonsil cancer resulted in good local cancer control and no recurrence on the untreated side.
Oropharyngeal cancer patients treated with combined chemotherapy & radiation therapy suffer from lower voice & speech quality for up to 1 year after treatment.
Limiting radiation to major salivary glands in head and neck cancer patients to reduce side effects was reported as feasible and safe in a medical conference.
New research suggests that valproic acid, a drug used to treat epilepsy and bipolar disorder, could help reduce the risk of developing head and neck cancer.
Two biomarkers have been found capable of predicting the effectiveness of radiation treatments for patients with squamous cell cancer of the head and neck.
Poor oral health and poor dental care both increase the risk of oral cancer. Using mouthwash more than 3 times a day also increased the risk of mouth cancers.